Dimitrios has a long-standing experience in various aspects of radiopharmaceutical development. Through his work at Algeta/Bayer, where he held the position of Head of Radiopharmaceutical Development, he became one of the pioneers in the field of CMC development of targeted alpha pharmaceuticals. Previously, Dimitrios contributed to the development and commercialization of multiple radiopharmaceuticals at GE Healthcare. Dimitrios obtained his Master's Degree in Biochemistry at the University of Oslo.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.